Turtle Cameron 4

What Happened
Turtle Cameron, CEO of Spyre Therapeutics (SYRE), sold a total of 15,000 shares on February 2, 2026 in open-market/private sales, for aggregate proceeds of approximately $492,045. The sales consisted of 957 shares at a weighted average price of $31.82 (≈ $30,452) and 14,043 shares at a weighted average price of $32.87 (≈ $461,593). These were sales (not purchases), which are often routine executive liquidity events rather than an explicit bullish signal.

Key Details

• Transaction dates: February 2, 2026 (reported on Form 4 filed February 4, 2026). Filing appears timely (filed within the typical 2-business-day window).
• Prices and ranges: reported weighted averages $31.82 and $32.87; underlying trade prices ranged $31.42–$32.05 for one group and $32.48–$33.35 for the other. Reporting person can provide exact per-trade breakdown on request (per footnotes).
• 10b5-1 plan: At least one of the transactions was executed pursuant to a Rule 10b5-1 trading plan adopted June 20, 2025.
• Shares owned after transaction: Not specified in the provided excerpt. Footnotes indicate holdings include 145,198 shares that vest monthly over roughly one year (service-based) and 633 shares acquired via the company’s ESPP (Aug 15, 2024).
• Footnotes: F2/F5 note weighted-average pricing and ranges; F1 notes the 10b5-1 plan; F3/F4 describe items included in ownership counts.

Context

• Sales under a pre-established 10b5-1 plan are pre-scheduled and generally limit inferences about insider sentiment.
• These were straight sales (transaction code S). No option exercises, gifts, or tax-withhold events were reported in the provided excerpt.
• For more detail (exact per-trade prices, post-transaction holdings), consult the full Form 4 filing (Accession 0001758363-26-000005).